Xbrane Biopharma will be hoping that the third time is the charm for its proposed US biosimilar to Genentech’s Lucentis (ranibizumab). Having already filed a biologics license application for the candidate twice with the US Food and Drug Administration and been knocked back both times, the Swedish biosimilars developer is now making a third attempt to gain approval for the ophthalmic treatment.
The Third Time’s The Charm? Xbrane Resubmits Ranibizumab In US
Follows Two Previous Knockbacks From FDA Over Lucentis Biosimilar
Xbrane is taking a third shot at filing its ranibizumab biosimilar rival to Lucentis with the US Food and Drug Administration. Will it succeed where it has previously failed to gain approval?

More from Biosimilars
Organon has swelled its immunology biosimilar portfolio after acquiring the US commercial rights to Bio-Thera’s tocilizumab biosimilar from Biogen, which last year decided to retain its interests in biosimilars following a lengthy strategic review.
Alvotech has named two new key executives, while Biosimilars Canada has elected its 2025 leaders and the AAM has welcomed the new FDA commissioner in the US.
Gedeon Richter has filed its Mochida-partnered tocilizumab biosimilar rival to RoActemra with the European Medicines Agency. But with several biosimilars already having won approval, the market could be competitive.
Accord received positive opinions for its Prolia and Xgeva biosimilars at the latest meeting of the EMA’s CHMP. Meanwhile, Celltrion picked up a nod for another Stelara biosimilar, while Rechon Life Science withdrew an application for human insulin.
More from Generics Bulletin
Off-patent drug trade groups expressed their concerns that personnel and expertise cuts will affect the agency’s ability to review and approve generics and biosimilars.
Amid ongoing generic drug supply problems, Japan's government is to set up a new fund to support corporate investments geared towards manufacturing and consolidation.
FDA staffing cuts are making negotiation preparations more difficult, but also could mean the result is a smaller user fee renewal package.